These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7650258)

  • 1. Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.
    Kihara M; Ikeda Y; Takagi N; Fujita H; Shibata K; Masumori S; Shiratori K; Umemura S; Shionoiri H; Ishii M
    Intensive Care Med; 1995 Apr; 21(4):348-51. PubMed ID: 7650258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of slowly performed daytime hemodialysis (slow HD) on the pharmacokinetics of vancomycin in hemodynamically unstable patients with renal failure.
    Kihara M; Ikeda Y; Fujita H; Tamura K; Yabana M; Takagi N; Umemura S; Ishii M
    Blood Purif; 1996; 14(1):20-5. PubMed ID: 8718561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M; Ikeda Y; Shibata K; Masumori S; Ebira H; Shiratori K; Ueda S; Takagi N; Umemura S; Shionoiri H
    Clin Nephrol; 1994 Sep; 42(3):193-7. PubMed ID: 7994939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration.
    D'Arcy DM; Casey E; Gowing CM; Donnelly MB; Corrigan OI
    BMC Pharmacol Toxicol; 2012 Nov; 13():14. PubMed ID: 23136834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.
    Stass H; Corkery K; Gribben D; Eldon MA
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):191-9. PubMed ID: 21599533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis of amikacin in critically ill patients.
    Armstrong DK; Hodgman T; Visconti JA; Reilley TE; Garner WL; Dasta JF
    Crit Care Med; 1988 May; 16(5):517-20. PubMed ID: 3359790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis.
    Pechere JC; Dugal R; Pechere MM
    Eur J Drug Metab Pharmacokinet; 1979; 4(1):49-56. PubMed ID: 467467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy.
    Taccone FS; de Backer D; Laterre PF; Spapen H; Dugernier T; Delattre I; Wallemacq P; Vincent JL; Jacobs F
    Int J Antimicrob Agents; 2011 Jun; 37(6):531-5. PubMed ID: 21489756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Roger C; Wallis SC; Muller L; Saissi G; Lipman J; Lefrant JY; Roberts JA
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4901-9. PubMed ID: 27270279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid losses and nitrogen balance during slow diurnal hemodialysis in critically ill patients with renal failure.
    Kihara M; Ikeda Y; Fujita H; Miura M; Masumori S; Tamura K; Yabana M; Takagi N; Umemura S; Ishii M
    Intensive Care Med; 1997 Jan; 23(1):110-3. PubMed ID: 9037649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration.
    Kinowski JM; de la Coussaye JE; Bressolle F; Fabre D; Saissi G; Bouvet O; Galtier M; Eledjam JJ
    Antimicrob Agents Chemother; 1993 Mar; 37(3):464-73. PubMed ID: 8460915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and dosage regimens of amikacin in intensive care unit patients.
    Debord J; Voultoury JC; Lachatre G; Favereau JP; Gay R
    Int J Biomed Comput; 1994 Jun; 36(1-2):135-7. PubMed ID: 7927853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and clearance of ciprofloxacin and amikacin in continuous hemodialysis].
    Cotera A; Aguila R; Gaete L; Saffie A; Lorca E; Thambo S
    Rev Med Chil; 1995 Jun; 123(6):742-8. PubMed ID: 8525228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of amikacin dosing schedule in critically ill elderly patients with different stages of renal dysfunction.
    Ghaffari S; Hadi AM; Najmeddin F; Shahrami B; Rouini MR; Najafi A; Mojtahedzadeh M
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e67-e71. PubMed ID: 34588225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and intramuscular bioavailability of amikacin in chickens following single and multiple dosing.
    el-Gammal AA; Ravis WR; Krista LM; Tolbert DS; Saad A
    J Vet Pharmacol Ther; 1992 Jun; 15(2):133-42. PubMed ID: 1433475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey.
    Fielding RM; Moon-McDermott L; Lewis RO; Horner MJ
    Antimicrob Agents Chemother; 1999 Mar; 43(3):503-9. PubMed ID: 10049258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency.
    Haubitz M; Bohnenstengel F; Brunkhorst R; Schwab M; Hofmann U; Busse D
    Kidney Int; 2002 Apr; 61(4):1495-501. PubMed ID: 11918757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.